Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin scans may predict who responds to dupilumab for eczema

NCT ID NCT07098000

Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are studying whether a non-invasive skin imaging technique called reflectance confocal microscopy can predict how well people with moderate to severe atopic dermatitis respond to dupilumab. The trial enrolls 40 participants aged 6 months and older who are starting dupilumab. By comparing baseline skin features seen under the microscope with changes in eczema severity scores over 24 weeks, the team aims to identify patterns that distinguish responders from non-responders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dupilumab
What this could lead to
If the approach works, doctors could use a non-invasive skin scan to predict who will respond to dupilumab and adjust treatment earlier, possibly reducing the need for skin biopsies.
What could go wrong
This is a small observational study of 40 people, so the findings may not apply broadly. Confocal microscopy is not widely available, and the link between skin features and treatment response may turn out to be weak or inconsistent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Apr 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll patients from the Buenos Aires Metropolitan Area (population \~14 million), where an estimated 3% of adults and 5% of children are affected by AD, with moderate-to-severe cases representing approximately 0.3%-0.5%. Dermatologists and allergists across all sectors-public, private, and social security-will be invited to refer eligible patients prior to dupilumab treatment initiation. Inclusion will not be restricted by insurance status or care setting, ensuring demographic and socioeconomic diversity.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥6 months of age. * Diagnosis of AD based on Hanifin and Rajka criteria. * Moderate-to-severe AD defined by: EASI \>16, BSA \>10%, SCORAD \>25, or vIGA-AD 3-4. * Starting dupilumab for AD indicated and initiated by the attending physician. * Signed informed consent or assent with guardian approval. * In those with previous systemic treatment (jaki, oral steroids, methotrexate and phototherapy), a predefined wash-out time of 4 weeks must be guaranteed. Exclusion Criteria: * Inability to comply with study procedures. * Refusal to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Hospital Italiano de Buenos Aires

    Buenos Aires, 1199, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.